SAHPRA allows use of Merck COVID-19 treatment pill

The South African Health Products Regulatory Authority (SAHPRA) announced on Thursday that Merck’s COVID-19 therapy tablet Molnupiravir had been approved for usage.
Pfizer had submitted an application for its COVID-19 tablet, Paxlovid, which was under consideration, according to SAHPRA. “The approval of Molnupiravir for compassionate use adds to the treatment options for COVID-19,” said SAHPRA Chief Executive Boitumelo Semete-Makokotlela.
Molnupiravir is only recommended for patients aged 18 and up, according to SAHPRA. It granted permission for the importation of a restricted number of molnupiravir capsules for a six-month term, subject to certain criteria.

Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn

Advertisement: Download Vital Signs App (VS App)